Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 21, 2020, William T. McKee informed the board of directors (the
"Board") of Agile Therapeutics, Inc. (the "Company") that he would retire as a
Class II director effective June 9, 2020, the date of the Company's 2020 Annual
Meeting of Stockholders (the "Annual Meeting"). The Company expressed gratitude
to Mr. McKee for his contributions to the Board and the Company. Mr. McKee's
departure is not related to any disagreement with the Company or the Board
regarding any matter related to the Company's operations, policies or practices.
Item 8.01. Other Events.
On April 22, 2020, the Company issued a press release announcing that Abhijeet
Lele would not stand for re-election as a Class III director at the Annual
Meeting. Further, the Company announced that it has nominated Sharon Barbari to
stand for election to the Board at the Annual Meeting to replace Mr. Lele as a
Class III member of the Board, for a term expiring at the 2023 Annual Meeting of
Stockholders. Ms. Barbari has over 40 years of pharmaceutical and biotechnology
experience, having served in various senior financial roles, including Chief
Financial Officer, at several companies during her career, including
Cytokinetics, InterMune and Gilead Sciences. Additionally, the Company announced
that it intends to appoint Sandra Carson, M.D. to replace Mr. McKee as a Class
II member of the Board following his retirement effective June 9, 2020. Dr.
Carson is a Professor of Obstetrics, Gynecology and Reproductive Sciences and
Director, Reproductive Endocrinology and Infertility at Yale University. Most
recently, she served as the Emeritus Vice President for Education at the
American College of Obstetricians & Gynecologists (ACOG) from August 2018 to
February 2019 and Vice President for Education from March 2013 to August
2018. The Company also announced that the Company's Board plans to appoint Seth
H.Z. Fischer as the lead independent director to replace Mr. Lele at the Annual
Meeting on June 9, 2020.
A copy of the Company's press release is filed as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number Description
99.1 Press Release dated April 22, 2020
© Edgar Online, source Glimpses